OTS: Qiagen N.V. / QIAGEN gibt Konditionen der neuen ...

OTS: Qiagen N.V. / QIAGEN gibt Konditionen der neuen ...

WKN: A2DKCH ISIN: NL0012169213 QIAGEN N.V.

29,13 EUR
0,02 EUR 0,08 %
23.10.2017 - 17:59
06.09.2017 16:57:40

QIAGEN gibt Konditionen der neuen Wandelschuldverschreibungen bekannt

Venlo, Niederlande (ots) -

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED

STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR

JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD

BE UNLAWFUL. NOT FOR DISTRIBUTION TO ANY U.S. PERSON. PLEASE SEE THE

IMPORTANT NOTICE AT THE END OF THIS PRESS RELEASE.

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) gibt

bestimmte Konditionen der neuen nicht-nachrangigen, unbesicherten

Wandelschuldverschreibungen mit Barausgleich (die

"Schuldverschreibungen") bekannt.

Das Emissionsvolumen der Schuldverschreibungen wurde auf einen

Gesamtnennbetrag von $400 Millionen erhöht. Die Schuldverschreibungen

werden mit 0,50% p.a. verzinst und die Zinsen jeweils halbjährlich

nachträglich zahlbar sein. Der anfängliche Wandlungspreis wird

voraussichtlich mit einer Wandlungsprämie von 30% über dem

Referenzaktienkurs am Tag der Preisfestsetzung festgesetzt. Der

Referenzaktienkurs entspricht dem volumengewichteten

durchschnittlichen Kurs der QIAGEN-Aktie zwischen Handelsbeginn und

Handelsschluss an dem NASDAQ Global Select Market am 6. September

2017.

Die endgültigen Konditionen der Schuldverschreibungen und das

endgültige Emissionsvolumen wird bei der endgültigen Preisfestsetzung

bestimmt, die voraussichtlich nach Handelsschluss an dem NASDAQ

Global Select Market am 6. September 2017 durchgeführt wird.

Nach den Bedingungen für die Platzierung der

Schuldverschreibungen, wird QIAGEN vereinbaren, für einen Zeitraum,

der 90 Tage nach dem Valutatag endet (lock-up period), keine

Wertpapiere, die im Wesentlichen mit den Schuldverschreibungen oder

QIAGEN-Aktien vergleichbar sind, zu verkaufen, vorbehaltlich üblicher

Ausnahmen.

Über QIAGEN

QIAGEN N.V., eine niederländische Holdinggesellschaft, ist der

weltweit führende Anbieter von Komplettlösungen zur Gewinnung

wertvoller molekularer Erkenntnisse aus biologischen Proben. Die

Probentechnologien von QIAGEN ermöglichen die Aufreinigung und

Verarbeitung von DNS, RNS und Proteinen aus Blut, Gewebe und anderen

Stoffen. Testtechnologien machen diese Biomoleküle sichtbar und

bereit zur Analyse. Bioinformatik-Lösungen und Wissensdatenbanken

helfen bei der Interpretation von Daten zur Gewinnung relevanter und

praktisch nutzbarer Erkenntnisse. Automationslösungen integrieren

diese zu nahtlosen und kosteneffizienten molekularen Test-Workflows.

QIAGEN stellt diese Workflows weltweit mehr als 500.000 Kunden aus

den Bereichen Molekulare Diagnostik (Gesundheitsfürsorge), Angewandte

Testverfahren (Forensik, Veterinärdiagnostik und

Lebensmittelsicherheit), Pharma (pharmazeutische und

biotechnologische Unternehmen) sowie Forschung (Life Sciences) zur

Verfügung. Zum 30. Juni 2017 beschäftigte QIAGEN weltweit rund 4.600

Mitarbeiter an über 35 Standorten. Weitere Informationen über QIAGEN

finden Sie unter http://www.qiagen.com.

Einige der Angaben in dieser Pressemitteilung können im Sinne von

Paragraph 27A des U.S. Securities Act (US-Aktiengesetz) von 1933 in

ergänzter Fassung und Paragraph 21E des U.S. Securities Exchange Act

(US-Aktienhandelsgesetz) von 1934 in ergänzter Fassung als

zukunftsgerichtete Aussagen ("forward-looking statements") gelten.

Soweit in dieser Meldung zukunftsgerichtete Aussagen über QIAGENs

Produkte, Kollaborationen, Märkte, Strategie und operative Ergebnisse

gemacht werden, einschließlich aber nicht begrenzt auf die zu

erwartenden Ergebnisse für den bereinigten Nettoumsatz und den

bereinigten verwässerten Gewinn je Aktie, bereinigter Bruttogewinn,

bereinigtes Operatives Ergebnis, bereinigtes Konzernergebnis,

anteilig für die Inhaber der QIAGEN N.V. und Free Cash Flow

Ergebnisse, geschieht dies auf der Basis derzeitiger Erwartungen und

Annahmen, die mit vielfältigen Unsicherheiten und Risiken verbunden

sind. Dazu zählen unter anderem: Risiken im Zusammenhang mit

Wachstumsmanagement und internationalen Geschäftsaktivitäten

(einschließlich Auswirkungen von Währungsschwankungen und der

Abhängigkeit von regulatorischen sowie Logistikprozessen),

Schwankungen der Betriebsergebnisse und ihre Verteilung auf unsere

Kundengruppen, die Entwicklung der Märkte für unsere Produkte an

Kunden in der Akademischen Forschung, Pharma, Angewandte

Testverfahren und Molekulare Diagnostik; Veränderung unserer

Beziehungen zu Kunden, Lieferanten und strategischen Partnern, das

Wettbewerbsumfeld, schneller oder unerwarteter technologischer

Wandel, Schwankungen in der Nachfrage nach QIAGEN-Produkten

(einschließlich allgemeiner wirtschaftlicher Entwicklungen, Höhe und

Verfügbarkeit der Budgets unserer Kunden und sonstiger Faktoren),

Möglichkeit die regulatorische Zulassung für unsere Produkte zu

erhalten, Schwierigkeiten bei der Anpassung von QIAGENs Produkten an

integrierte Lösungen und die Herstellung solcher Produkte, die

Fähigkeit des Unternehmens neue Produktideen zu entwickeln,

umzusetzen und sich von den Produkten der Wettbewerber abzuheben

sowie vor dem Wettbewerb zu schützen, Marktakzeptanz neuer Produkte

und die Integration akquirierter Geschäfte und Technologien. Weitere

Informationen finden Sie in Berichten, die QIAGEN bei der U.S.

Securities and Exchange Commission (US-Börsenaufsichtsbehörde)

eingereicht hat.

Disclaimer:

The contents of this press release have been prepared by and are

the sole responsibility of QIAGEN and the information contained in

this press release is for background purposes only and does not

purport to be full or complete. No reliance may be placed by any

person for any purpose on the information contained in this press

release or its accuracy, fairness or completeness.

The distribution of this press release and the offer and sale of

the Notes in certain jurisdictions may be restricted by law. The

Notes may not be offered to the public in any jurisdiction in

circumstances which would require the preparation or registration of

any prospectus or offering document relating to the Notes in such

jurisdiction. No action has been taken by QIAGEN or any of the Joint

Bookrunners or any of their respective affiliates that would permit

an offering of the Notes or possession or distribution of this press

release or any other offering or publicity material relating to such

securities in any jurisdiction where action for that purpose is

required. Persons into whose possession this press release comes are

required to inform themselves about and to observe any such

restrictions.

This press release is for information purposes only and does not

constitute or form a part of an offer to sell or a solicitation of an

offer to purchase any security of QIAGEN in the United States or in

any other jurisdiction where such offer or solicitation is unlawful.

The Notes described in this press release have not been and will not

be registered under the U.S. Securities Act of 1933, as amended (the

"Securities Act"), or any applicable state or foreign securities

laws. The securities described in this press release may not be

offered or sold in the United States or to any U.S. person absent

registration or an exemption from the registration requirements of

the Securities Act. There shall be no public offering of the Notes in

the United States.

Neither this press release nor any copy of it may be taken,

transmitted or distributed, directly or indirectly in or into the

United States, Canada, Australia, Japan, South Africa or any other

state or jurisdiction in which such action would be unlawful. Any

failure to comply with this restriction may constitute a violation of

United States, Canadian, Australian, Japanese, South African or other

applicable securities laws.

For readers in the European Economic Area: In any EEA Member State

that has implemented the Prospectus Directive, this communication is

only addressed to and directed at qualified investors in that Member

State within the meaning of the Prospectus Directive. The term

"Prospectus Directive" means Directive 2003/71/EC (and amendments

thereto, including Directive 2010/73/EU, to the extent implemented in

each relevant Member State), together with any relevant implementing

measure in the relevant Member State.

For readers in the United Kingdom: This communication is being

directed only at (i) persons who are outside the United Kingdom or

(ii) investment professionals falling within Article 19(5)

("Investment professionals") of the Financial Services and Markets

Act 2000 (Financial Promotion) Order 2005 (the "Order") or (iii)

certain high value persons and entities who fall within Article

49(2)(a) to (d) ("High net worth companies, unincorporated

associations etc.") of the Order; or (iv) any other person to whom it

may lawfully be communicated (all such persons in (i) to (iv)

together being referred to as "relevant persons"). The Notes are only

available to, and any invitation, offer or agreement to subscribe,

purchase or otherwise acquire such Notes will be engaged in only

with, relevant persons. Any person who is not a relevant person

should not act or rely on this document or any of its contents.

The Joint Bookrunners, each of which are authorized by the

Prudential Regulation Authority and regulated by the Financial

Conduct Authority and the Prudential Regulation Authority, are acting

exclusively for QIAGEN and no-one else in connection with the offer

and sale of the Notes (the "Offering"). They will not regard any

other person as their respective clients in relation to the Offering

and will not be responsible to anyone other than QIAGEN for providing

the protections afforded to their respective clients, nor for

providing advice in relation to the Offering, the contents of this

announcement or any transaction, arrangement or other matter referred

to herein.

In connection with the Offering, the Joint Bookrunners and any of

their affiliates, may take up a portion of the Notes in the Offering

as a principal position and in that capacity may retain, purchase,

sell, offer to sell for their own accounts such Notes and other

securities of the Company or related investments in connection with

the Offering or otherwise. Accordingly, references herein to the

Notes being issued, offered, subscribed, acquired, placed or

otherwise dealt in should be read as including any issue or offer to,

or subscription, acquisition, placing or dealing by, the Joint

Bookrunners and any of their affiliates acting in such capacity. In

addition, the Joint Bookrunners and any of their affiliates may enter

into financing arrangements (including swaps or contracts for

differences) with investors in connection with which the Joint

Bookrunners and any of their affiliates may from time to time

acquire, hold or dispose of Notes. The Joint Bookrunners do not

intend to disclose the extent of any such investment or transactions

otherwise than in accordance with any legal or regulatory obligations

to do so.

None of the Joint Bookrunners or any of their respective

directors, officers, employees, advisers or agents accepts any

responsibility or liability whatsoever for or makes any

representation or warranty, express or implied, as to the truth,

accuracy or completeness of the information in this press release (or

whether any information has been omitted from the press release) or

any other information relating to QIAGEN, its subsidiaries or

associated companies, whether written, oral or in a visual or

electronic form, and howsoever transmitted or made available or for

any loss howsoever arising from any use of this press release or its

contents or otherwise arising in connection therewith.

In connection with the Notes Offering, QIAGEN intends to enter

into privately negotiated convertible note hedge transactions with

one or more Joint Bookrunners for the Notes offering or other

financial institutions (the "dealers") or their affiliates, initially

covering the same number of QIAGEN's common shares as underlie the

Notes. The convertible note hedge transactions will be cash settled

upon exercise and are expected to offset any cash payments QIAGEN is

required to make in excess of the principal amount of the Notes upon

conversion. QIAGEN also intends to enter into separate privately

negotiated warrant transactions with such dealers or their

affiliates, initially covering the same number of QIAGEN's common

shares as underlie the Notes. The warrant transactions could

separately have a dilutive effect with respect to QIAGEN's common

shares to the extent that the market price per share of QIAGEN's

common shares upon expiration of the warrants exceeds the strike

price of the warrants, which is expected to be set around 160% of the

Reference Share Price.

In connection with these Convertible Note Hedge and Warrant

Transactions, such dealers or their affiliates expect to enter into

various derivatives transactions and engage in other activities that

could have the effect of increasing or preventing a decline in the

price of QIAGEN's common stock in connection with the pricing of the

Notes offering. These activities may be discontinued at any time. In

addition, from time to time and in connection with any conversion of

the Notes, the dealers or their respective affiliates may enter into

or unwind derivative transactions and engage in other activities that

could adversely impact the price of QIAGEN's common stock and of the

Notes.

OTS: Qiagen N.V.

newsroom: http://www.presseportal.de/nr/76066

newsroom via RSS: http://www.presseportal.de/rss/pm_76066.rss2

ISIN: NL0012169213

Pressekontakt:

Public Relations:

Dr. Thomas Theuringer

Senior Director Public Relations and Digital Communications

+49 2103 29 11826

Email: pr@qiagen.com

www.twitter.com/qiagen

https://www.facebook.com/QIAGEN

pr.qiagen.com

Investor Relations:

John Gilardi

Vice President Corporate Communications and Investor Relations

+49 2103 29 11711

Email: ir@qiagen.com

ir.qiagen.com

Aktien in diesem Artikel

QIAGEN N.V. 29,15 0,14% QIAGEN N.V.

Aktienempfehlungen zu QIAGEN N.V.

  • Alle
  • Buy
  • Hold
  • Sell
19.09.17 QIAGEN buy Joh. Berenberg, Gossler & Co. KG (Berenberg Bank)
06.09.17 QIAGEN Hold Warburg Research
28.08.17 QIAGEN Halten DZ BANK
17.08.17 QIAGEN buy Commerzbank AG
17.08.17 QIAGEN buy Joh. Berenberg, Gossler & Co. KG (Berenberg Bank)
mehr Aktienempfehlungen

Indizes in diesem Artikel

NASDAQ Comp. 6.586,83
-0,64%

Nachrichten

  • Nachrichten zu Aktien
  • Alle Nachrichten
pagehit